UPDATE: CELGENE acquired Juno Therapeutics (JUNO) for $87 a Share
Another company in my Blog Portfolio, Juno Therapeutics (JUNO) will be acquired by Celgene Corp. (CELG) for $9 Billion or $87 a share in Cash. The initial news came last Tuesday, 1/16 and finally deal was announced today, 1/22/18. The stock has shot up from $45 early last week to $86 today, which is about 93% premium from the initial news. This is the 2nd biotech company from my Blog portfolio which got acquired! In August KITE got acquired by Gilead Sciences (GILD) with $180 a share. As you know, Juno Therapeutics Inc., a biotech company developing cancer treatments.
Thanks to all the participants who joined in our Investment Meet on Sunday 1/21/18.
Thanks to all the participants who joined in our Investment Meet on Sunday 1/21/18.
Comments
Post a Comment